Jim Cramer Just Can’t Stop Praising Johnson & Johnson (JNJ)

We recently published 15 Fresh Stocks Jim Cramer Discussed.  Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer discussed.

Jim Cramer has turned quite optimistic on pharmaceutical firm Johnson & Johnson (NYSE:JNJ) lately. Most of the CNBC TV host’s optimism stems from the firm’s cancer drug portfolio and its decision to spin off its orthopaedic business. The shares have gained 47.8% over the past year and by 5.5% year-to-date. Early in January, Bernstein raised Johnson & Johnson (NYSE:JNJ)’s share price target to $208 from $193 and kept a Market Perform rating on the shares, The Fly reported. The financial firm pointed towards clearer visibility into macroeconomic uncertainties as one factor behind the optimism. Cramer continued to praise Johnson & Johnson (NYSE:JNJ)’s business spinoff strategies and the cancer portfolio:

“I hope that the people at JPMorgan for their 44th Healthcare Conference don’t take this personally. This company did not present and I am now willing to say that after Eli Lilly it was the best. This has been a remarkable move, this is JNJ. Now it had been kept down, the talc lawsuits, they decided to stop that. . .

Sheila Fitzgerald / Shutterstock.com

Mar Vista U.S. Quality Strategy also discussed Johnson & Johnson (NYSE:JNJ) in its fourth quarter 2025 investor letter:

“Johnson & Johnson (NYSE:JNJ) stock demonstrated strong performance in Q4, driven by robust financial results, upward guidance revisions, and accelerating growth for the pharmaceutical and medical technology segments. The company’s consistent execution across key business segments and positive market sentiment, despite a significant headwind from Stelera generics, contributed to its outperformance relative to broader market indices. Management continues to expect 5-7% revenue growth through 2030 which exceeds consensus estimates.”